[HTML][HTML] Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
MR Garcia Campelo, C Zhou, SS Ramalingam… - Journal of Clinical …, 2022 - mdpi.com
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
MR Garcia Campelo, C Zhou… - Journal of Clinical …, 2023 - search.ebscohost.com
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
[PDF][PDF] Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
MR Garcia Campelo, C Zhou… - J. Clin …, 2023 - pdfs.semanticscholar.org
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
C Zhou, S Ramalingam, H Lin, T Kim… - Journal of Clinical …, 2022 - europepmc.org
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
MRG Campelo, C Zhou… - Journal of clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
MRG Campelo, C Zhou… - Journal of Clinical …, 2023 - snucm.elsevierpure.com
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
[HTML][HTML] Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
MRG Campelo, C Zhou, SS Ramalingam… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
MRG Campelo, C Zhou… - Journal of Clinical …, 2023 - search.proquest.com
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
[引用][C] Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
MR Garcia Campelo, C Zhou… - Journal of Clinical …, 2022 - repository.icr.ac.uk
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
GC MR, C Zhou, SS Ramalingam, HM Lin… - Journal of Clinical …, 2022 - europepmc.org
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …
inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in …